期刊文献+

硬骨鱼紧张素ⅡT21M基因多态性与东乡族原发性高血压关系的研究 被引量:2

Association of Urotensin Ⅱ T21M polymorphisms with essential hypertension from Dongxiang nationality
原文传递
导出
摘要 目的:研究硬骨鱼紧张素ⅡT21M基因(UTS2-T21M)单核苷酸多态性(SNP)与东乡族原发性高血压(EH)的关系。方法:用PCR-RFLP及电泳分析法进行基因分型;SPSS软件分析各基因型与东乡族人群EH的相关性。结果:研究包括120例东乡族EH患者及102例正常人。EH患者与对照组间在基因型,等位基因频率上均有显著差异(P=0.021,0.014)。UTS2-T21M多态性,TT,TM,MM基因型的频率在病例组中分别40.0%,43.3%,16.7%;对照组相应基因型的频率为22.5%,55.0%,22.5%。T,M等位基因频率在病例组中分别61.7%,38.3%,对照组相应的等位基因频率为50.0%,50.0%。结论:UTS2-T21M基因多态性与东乡族人群EH相关。 Objective:To study the association of UTS2-T21M SNP with essential hypertension in Dongxiang nationality.Method:Genotyping of UTS2-T21M was conducted with PCR-RFLP and agarose gel electrophoreticanalysis.All statistical analyses were performed with SPSS.Result:120 essential hypertension(EH) cases and 102 healthy controls were studied.We found significant difference in genotypic and allelic frequency of T21M SNP in UTS 2 between EH patients and controls.(P=0.021,and 0.014,respectively).Frequencies of TT,TM,MM Genotypes were 40.0%,43.3%,16.7% in case,And were 22.5%,55.0%,22.5% in controls;Frequencies of T,M allele were 61.7%,38.3% in case and 50.0%,50.0% in controls.Conclusion:Genetic variants of T21M of UTS2 were association with essential hypertension in Dongxiang population.
作者 伊琳
机构地区 甘肃中医学院
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2011年第1期41-43,共3页 Journal of Clinical Cardiology
基金 甘肃省自然科学基金(No:1010RJZA158)
关键词 原发性高血压 东乡族 单核苷酸多态性 硬骨鱼紧张素Ⅱ基因 Dongxiang population essential hypertension Single-nucleotide polymorphism
  • 相关文献

参考文献12

  • 1VOLKER RUPPERT, Bernhard Maischl: Genetics of Human Hypertension[J]. Herz, 2003, 28:655 - 662.
  • 2周林.高血压病的相关基因[J].国外医学(心血管疾病分册),1998,25(2):84-87. 被引量:15
  • 3COULOUARN Y, LIHRMANN 1, JEGOU S, et at. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cordl Proc [J]. Natl Acad Sci,1998,95:15803-15808.
  • 4OHSAKO S, ISHIDA I, ICHIKAWA T, et al. Cloning and sequence analysis ofcDNAs encoding precursors of urotensin Ⅱ 2a and 271[J]. J Neurosci,1986, 6:27302-27351.
  • 5GIBSON A. Complex effects of Gillicht hys urotensin Ⅱ on rat arotic st rips[J]. BrJ Pharmacol,1987,91: 205-212.
  • 6AMES R S, SARAU H M, CHAMBERS J K, et al. Human urotensin Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J]. Nature, 1999,401,282-286.
  • 7郭艳红,汪长华.尾加压素Ⅱ及其对心脏的调控作用[J].中国心脏起搏与心电生理杂志,2005,19(2):153-154. 被引量:2
  • 8SHENOUDA A, DOUGLAS S A, OHLSTEIN E H, et al. Localization of urotensin Ⅱ immunoreactivity in normal human kidneys and renal carcinomal[J]. J Histochem Cytochem, 2002,50 : 885 - 890.
  • 9张珺辉,张靖溥.尾加压素Ⅱ与高血压病的相关性[J].中国全科医学,2003,6(8):640-641. 被引量:16
  • 10祝方,纪立农,罗斌.硬骨鱼紧张素Ⅱ基因多态性与中国人2型糖尿病遗传易感性的关系[J].中华医学杂志,2002,82(21):1473-1475. 被引量:24

二级参考文献39

  • 1MANCIA G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction[J]. Acta Diabetol, 2005, 42: S17-25.
  • 2MANCIA G, DE BACKER G,DOMINICZAK A, et al. 2007 Guidelines for the management of arterial hypertension.. The Task Foi'ce for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European, Society of Cardiology (ESC)[J]. Eur Heart J,2007,28: 1462- 1536.
  • 3VASOVIC O,ZAMAKLAR M,LALIC K, et al. The prevalence of hypertension and microalbuminuria in diabetes mellitus type 1 and type 2[J].Srp Arh Celok Lek, 2005,133:229-232.
  • 4QIAO Q, JOUSILAHTI P, ERIKSSON J,et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up[J]. Diabetes Care, 2003,26 : 2910 - 2914.
  • 5ECKEL R H, GRUNDY S M, ZIMMET P Z. The metabolic syndrome[J].Lancet, 2005, 365: 1415-1428.
  • 6GROOP L C. Insulin resistance:the fundamental trigger of type 2 diabetes[J].Diabetes Obes Metab, 1999,1(Suppl 1) :S1-7.
  • 7LI Y B, XU W, LIAO Z H, et al. Induction of long- term glycemic control in newly diagnosed type 2 dia- betic patients is associated with improvement of βcell function[J]. Diabetes Care, 2004, 27 : 2597-2602.
  • 8WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1 : diagnosis and classification of diabetes mellitus[S]. Geneva : World Health Organisation, 1999.
  • 9ABDUL-GHANI MA,TRIPATHY D, DE FRONZO RA. Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose[J].Diabetes Care,2006,29:1130-1139.
  • 10UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose eontrol with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [J]. Lancet, 1998,352 : 854-865.

共引文献61

同被引文献14

  • 1Pehlivan Y, Onat AM, Cornez G, el al. Urotensin II in systemic sclerosis: a new peptide in pathogenesis [J]. Clin Rheumatol, 2011, 30 (6): 837 842.
  • 2Rodrigo R, Gonztilez J, Paoletto F. The role of oxidative stress in the pathophysiology of [J]. Hypertens Res, 2011, 34 (4): 431-440.
  • 3Matsushita M, Shichiri M, Imai T, et al. Co expression of urotensin I1 and its receptor (GPR14) in humancardiovascular and renal tissues [J]. Hypertension, 2001, 19 (3): 2185 -2190.
  • 4Mosenkis A, Kallem RR, Danoff TM, al. Renal impairment, hypertension and plasma urotensin II [J]. NephrolDial Transplant, 2011, 26 (2): 609-614.
  • 5Kiss RS, You Z, Genest J, et al. Urotensin Ⅱdifferentially regulates macrophage and hepatic cholesterolhomeostasis[J].Peptides, 2011, 32 (5): 956-963.
  • 6Suguro T, Watanabe T, Kodate S, et al. Increased plasma urotensin II levels are associated with diabetic retinopathy and carotid atheroselerosis in type 2 diabetes [J]. Clin Sci, 2008, 115 (11): 327-334.
  • 7Takahashi K. Urotensin Ⅱ[J]. Nippon Rinsho, 2010, 68 (Suppl 7): 640-644.
  • 8Watanabe T, Arita S, Shiraishi Y, et al. Human urotensin Ⅱ promotes hypertension and atherosclerotic cardiovascular diseases [J]. Curr MedChem, 2009, 16 (5): 550-563.
  • 9Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis invascular smooth muscle cells [J]. Circulation, 2001, 104 (1) .. 16-18.
  • 10Maguire J J, Kuc RE, Davenport AP. Orphan receptor ligand human urotensin Ⅱ receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1 [J]. Br J Pharmacol, 2000, 131 (3), 441- 446.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部